Overcoming Challenges for Schedule III Opioids and Non-Opioid Products

January 30, 2018 4:00pm

John A. Gilbert Jr.
Hyman, Phelps & McNamara, PC (Washington, DC)

  • Examining the impact of disparate federal and state regulation of non-opioid drugs
    • Considering state legislative efforts to overcome hurdles for clinical trial execution and patient access
  • Ensuring compliance with special regulations for Buprenorphine, Suboxone, and other schedule III drugs for addiction treatment
  • Updates on cannabis research for use in epilepsy/seizure disorders and rare pediatric disorders
    • Status of pending legislation to reschedule marijuana